Genting Hong Kong (01952.HK) revenue increased by 48% in the first half of 2025, with full-year revenue expected to be between 16 and 18 billion.

According to the Wisdom Finance APP, on August 29, Hong Kong Stock Exchange's innovative pharmaceutical company Yun Ding Xinyao (01952.HK) released its midterm performance report and latest business developments as of June 30, 2025. Multiple core indicators performed outstandingly, with commercialization and research and development working together synergistically, demonstrating strong growth resilience and laying a solid foundation for breaking through to become a global leading Biopharma company.